VISX INVESTORS STARRY-EYED IN ANTICIPATION OF FDA PRK APPROVAL; STOCK LEADS NOVEMBER O-T-C DEVICE INDEX WITH 53.9% ADVANCE; COMPOSITE UP 7.8%
This article was originally published in The Gray Sheet
Executive Summary
Visx' receipt of an FDA approvable letter for its Star excimer laser in photorefractive keratectomy helped shoot the firm's stock up 12-1/8 points (53.9%) to 34-5/8 in November. The jump was the largest in points and percentage on "The Gray Sheet" O-T-C Index for the month.